LLY · 10-Q · 2026Q2 · Full report
Outstanding Indebtedness
ELI LILLY & Co · 2026-08-05 · Importance 79 · Surprise 66 · In source text
Lilly issued $9.0 billion of long-term debt in May 2026 for general corporate purposes, commercial-paper repayment, and funding part of the upfront consideration and related costs for Centessa and Kelonia. Total debt increased $12.4 billion to $54.9 billion at June 30, 2026 from $42.5 billion at December 31, 2025. The debt increase supported acquisitions and other corporate funding needs. $10.0 billion of the company’s $10.1 billion in unused committed credit facilities was available for commercial paper support.
Key facts
- In May 2026, the Company issued long-term debt totaling $9.0 billion and used net cash proceeds for general corporate purposes including repayment of outstanding commercial paper and funding portion of upfront cash consideration for acquisitions of Centessa and Kelonia. source
- Total debt as of June 30, 2026: $54.9 billion, an increase of $12.4 billion compared with $42.5 billion as of December 31, 2025. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | realized | -8.7% | Total debt as of June 30, 2026: $54.9 billion, an increase of $12.4 billion compared with $42.5 billion as of December 31, 2025. |
| liability | negative | realized | -6.3% | In May 2026, the Company issued long-term debt totaling $9.0 billion and used net cash proceeds for general corporate purposes including… |